<SEC-DOCUMENT>0001999371-25-020336.txt : 20251215
<SEC-HEADER>0001999371-25-020336.hdr.sgml : 20251215
<ACCEPTANCE-DATETIME>20251215163210
ACCESSION NUMBER:		0001999371-25-020336
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251211
FILED AS OF DATE:		20251215
DATE AS OF CHANGE:		20251215

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GSK plc
		CENTRAL INDEX KEY:			0001131399
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		251572044

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0
		BUSINESS PHONE:		44 20 8047 5000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0

	FORMER NAME:	
		FORMER CONFORMED NAME:	GSK PLC
		DATE OF NAME CHANGE:	20220516

	FORMER NAME:	
		FORMER CONFORMED NAME:	GLAXOSMITHKLINE PLC
		DATE OF NAME CHANGE:	20010105

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>gsk-form4_121225.xml
<DESCRIPTION>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-12-11</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001631574</issuerCik>
        <issuerName>Wave Life Sciences Ltd.</issuerName>
        <issuerTradingSymbol>WVE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001131399</rptOwnerCik>
            <rptOwnerName>GSK plc</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>79 NEW OXFORD STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LONDON</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>WC1A 1DG</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2025-12-11</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1470000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>19.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>18245691</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Corporation</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the &quot;Reporting Person&quot;).</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Victoria Whyte, Authorized Signatory, GSK plc</signatureName>
        <signatureDate>2025-12-15</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
